Junji Uchida Selected Research

Hypoxia (Hypoxemia)

3/2022	Experience With the Use of a Novel Agent, Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, for Posttransplant Anemia in Renal Transplant Recipients: A Case Report.
3/2020	Effects of orally active hypoxia inducible factor alpha prolyl hydroxylase inhibitor, FG4592 on renal fibrogenic potential in mouse unilateral ureteral obstruction model.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Junji Uchida Research Topics

Disease

47	Neoplasms (Cancer) 08/2022 - 11/2002
30	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 11/2006
14	Chronic Kidney Failure (Chronic Renal Failure) 11/2020 - 03/2003
13	Lung Neoplasms (Lung Cancer) 01/2020 - 12/2006
11	Colorectal Neoplasms (Colorectal Cancer) 05/2015 - 03/2007
7	Neoplasm Metastasis (Metastasis) 04/2022 - 02/2003
7	Fibrosis (Cirrhosis) 03/2020 - 12/2002
6	Disease Progression 01/2022 - 01/2014
5	Diabetes Mellitus 03/2022 - 05/2011
5	Ureteral Obstruction 03/2020 - 12/2002
5	Cardiovascular Diseases (Cardiovascular Disease) 07/2011 - 09/2002
4	Carcinoma (Carcinomatosis) 04/2022 - 02/2014
4	Infections 11/2020 - 01/2011
4	Breast Neoplasms (Breast Cancer) 06/2020 - 01/2010
4	Stomach Neoplasms (Stomach Cancer) 01/2018 - 01/2005
4	Renal Cell Carcinoma (Grawitz Tumor) 02/2014 - 04/2003
3	Body Weight (Weight, Body) 03/2022 - 05/2009
3	Anemia 03/2022 - 03/2020
3	Proteinuria 01/2022 - 01/2015
3	Pleural Effusion (Pleural Effusions) 01/2022 - 03/2015
3	Insulin Resistance 06/2019 - 05/2011
3	Glucose Intolerance 06/2019 - 05/2011
3	Inflammation (Inflammations) 01/2019 - 04/2005
3	Albuminuria 11/2018 - 07/2011
3	Adenocarcinoma of Lung 01/2016 - 12/2011
3	Colonic Neoplasms (Colon Cancer) 07/2012 - 05/2009
2	Fistula 09/2022 - 01/2015
2	Frailty 03/2022 - 05/2020
2	Hypoxia (Hypoxemia) 03/2022 - 03/2020
2	Acute Kidney Injury (Acute Renal Failure) 01/2022 - 01/2021
2	Pneumonia (Pneumonitis) 01/2021 - 01/2021
2	Malignant Pleural Effusion 02/2020 - 01/2020
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2020 - 09/2011
2	Ischemia 01/2019 - 08/2002
2	Neutropenia 07/2017 - 08/2014
2	Nausea 06/2017 - 11/2006
2	Vomiting 06/2017 - 11/2006

Drug/Important Bio-Agent (IBA)

12	ErbB Receptors (EGF Receptor)IBA 01/2022 - 03/2008
11	Tyrosine Kinase InhibitorsIBA 01/2022 - 03/2008
11	Fluorouracil (Carac)FDA LinkGeneric 03/2015 - 08/2007
8	pembrolizumabIBA 04/2022 - 01/2019
8	Leucovorin (Folinic Acid)FDA Link 01/2018 - 03/2007
7	Folic Acid (Vitamin M)FDA LinkGeneric 07/2017 - 03/2007
7	Circulating Tumor DNAIBA 12/2016 - 12/2011
5	Proteins (Proteins, Gene)FDA Link 03/2022 - 05/2011
4	Gemcitabine FDA Link 04/2022 - 11/2006
4	Cisplatin (Platino)FDA LinkGeneric 04/2022 - 02/2003
4	roxadustatIBA 03/2022 - 09/2019
4	AlbuminsIBA 01/2022 - 05/2011
4	Immune Checkpoint InhibitorsIBA 04/2021 - 01/2020
4	AntibodiesIBA 06/2020 - 05/2012
4	Rituximab (Mabthera)FDA Link 01/2019 - 08/2014
4	Thymidylate SynthaseIBA 07/2017 - 03/2008
4	DNA (Deoxyribonucleic Acid)IBA 09/2015 - 12/2011
4	Erlotinib Hydrochloride (CP 358,774)FDA Link 09/2015 - 02/2009
4	Gefitinib (Iressa)FDA Link 01/2015 - 03/2008
4	Paclitaxel (Taxol)FDA LinkGeneric 01/2013 - 01/2010
3	SteroidsIBA 03/2022 - 02/2020
3	Prolyl-Hydroxylase InhibitorsIBA 03/2022 - 03/2020
3	PlatinumIBA 01/2022 - 12/2019
3	Docetaxel (Taxotere)FDA Link 01/2022 - 09/2015
3	Pharmaceutical PreparationsIBA 01/2021 - 05/2015
3	Hemoglobins (Hemoglobin)IBA 01/2020 - 03/2015
3	Glucose (Dextrose)FDA LinkGeneric 06/2019 - 05/2011
3	AntigensIBA 01/2019 - 01/2009
3	Pemetrexed (MTA)FDA Link 07/2017 - 01/2014
3	Messenger RNA (mRNA)IBA 07/2017 - 05/2011
3	Biomarkers (Surrogate Marker)IBA 07/2017 - 01/2015
3	TegafurIBA 08/2013 - 11/2010
3	UracilIBA 08/2013 - 11/2010
3	Carboplatin (JM8)FDA LinkGeneric 01/2013 - 11/2006
2	Epidermal Growth Factor (EGF)IBA 01/2022 - 03/2015
2	RamucirumabIBA 01/2022 - 04/2021
2	osimertinibIBA 01/2022 - 01/2022
2	durvalumabIBA 01/2021 - 01/2021
2	Prolyl Hydroxylases (Prolyl Hydroxylase)IBA 06/2020 - 09/2019
2	Trastuzumab (Herceptin)FDA Link 06/2020 - 05/2010
2	Plasminogen Activator Inhibitor 1IBA 03/2020 - 01/2018
2	Indicators and Reagents (Reagents)IBA 01/2020 - 08/2015
2	LigandsIBA 01/2020 - 03/2015
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2018 - 07/2012
2	CytokinesIBA 07/2017 - 02/2014
2	EnzymesIBA 07/2017 - 08/2012
2	trifluridine tipiracil drug combinationIBA 05/2015 - 03/2015

Therapy/Procedure

33	Therapeutics 08/2021 - 05/2003
23	Drug Therapy (Chemotherapy) 04/2022 - 02/2003
16	Kidney Transplantation 11/2020 - 02/2003
9	Transplantation 05/2020 - 01/2003
7	Renal Dialysis (Hemodialysis) 08/2021 - 09/2002
4	Radiotherapy 04/2022 - 09/2011
4	Nephrectomy 01/2021 - 04/2003
4	Combination Drug Therapy (Combination Chemotherapy) 05/2015 - 03/2008
3	Chemoradiotherapy 01/2021 - 07/2014
3	Immunotherapy 02/2014 - 06/2004
2	Adjuvant Chemotherapy 04/2022 - 08/2007
2	Cystectomy 04/2022 - 11/2002
2	Prostatectomy (Retropubic Prostatectomy) 01/2022 - 12/2020
2	Conformal Radiotherapy 01/2021 - 12/2006
2	Renal Replacement Therapy (Therapies, Renal Replacement) 11/2020 - 01/2020
2	Aftercare (After-Treatment) 12/2016 - 07/2011